(2-(methoxymethyl)cyclopropyl)benzene | 64584-02-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2-(methoxymethyl)cyclopropyl)benzene
• 英文别名: 1-phenyl-cis-2-methoxymethylcyclopropane acid；1-Methoxymethyl-2-phenyl-cyclopropan；1-Phenyl-2-methoxymethyl-cyclopropan；[2-(Methoxymethyl)cyclopropyl]benzene
• CAS: 64584-02-7
• 化学式: C₁₁H₁₄O
• 分子量: 162.232
• InChiKey: RTOQKUJOINWWMO-UHFFFAOYSA-N

物化性质

• 沸点：
  225.6±9.0 °C(Predicted)
• 密度：
  1.005±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  烯丙基甲基醚 、 二氮杂甲苯 生成 (2-(methoxymethyl)cyclopropyl)benzene
  参考文献：
  名称：

  卡宾除3-取代丙烯外的极性选择性

  摘要：

  已经通过竞争性实验确定了将几种卡宾加入一系列烯丙基化合物中的相对速率常数。这些结果和推导的Hammett-Taft参数表明，碳烯的极性选择性通常较低，但与卡宾取代基的极性相关。单线态卡宾的选择性甚至低于相应的三线态。这些事实支持了加成单线碳烯的机理，该单线碳烯涉及由极性结构贡献很小的过渡态。烷氧羰基卡宾的低选择性表明，烷氧羰基的– R效应不会影响卡宾的加成反应性。

  DOI：

  10.1039/p29770001094

文献信息

• Preparation of a Storable Zinc Carbenoid Species and Its Application in Cyclopropanation, Chain Extension, and [2,3]-Sigmatropic Rearrangement Reactions
  作者：Arnaud Voituriez、Lucie E. Zimmer、André B. Charette

  DOI：10.1021/jo902618e

  日期：2010.2.19

  The formation of a new phosphate carbenoid (n-BuO)2P(O)OZnCH2I and its application in organozinc-mediated reactions is described. This carbenoid undergoes very slow degradation in solution and can be stored for several weeks at −20 °C. Its reactivity was tested with many representative alkenes and was determined to be a powerful cyclopropanating reagent, giving the corresponding cyclopropanes in 72−99%

  描述了一种新的磷酸盐类胡萝卜素（n -BuO）2 P（O）OZnCH 2 I的形成及其在有机锌介导的反应中的应用。该类胡萝卜素在溶液中的降解非常缓慢，可以在-20°C下保存数周。用许多代表性的烯烃测试了其反应活性，并确定其为强力的环丙烷化试剂，以72-99％的产率提供了相应的环丙烷。还描述了该类胡萝卜素在1,3-二酮扩链和[2,3]-σ重排反应中的用途。
• [EN] NOVEL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF<br/>[FR] NOUVEAUX BLOQUEURS DU CANAL POTASSIQUE ET LEURS UTILISATIONS
  申请人：BIONOMICS LTD

  公开号：WO2009149508A1

  公开（公告）日：2009-12-17

  The present invention relates to compounds useful in the modulation of potassium channel activity in cells, in particular the activity of Kv1.3 channels found in T cells. The invention also relates to the use of these compounds in the treatment or prevention of autoimmune and inflammatory diseases, including multiple sclerosis, pharmaceutical compositions containing these compounds and methods for their preparation.

  本发明涉及一种在细胞中调节钾通道活性的化合物，特别是用于T细胞中发现的Kv1.3通道的活性。该发明还涉及利用这些化合物治疗或预防自身免疫和炎症性疾病，包括多发性硬化症，含有这些化合物的药物组合物以及其制备方法。
• Heterocyclic compounds and methods of their use
  申请人：NOVARTIS AG

  公开号：US10370388B2

  公开（公告）日：2019-08-06

  The present invention relates to heterocyclic compounds useful for antagonizing angiotensin II Type 2 (AT2) receptor. More particularly the invention relates to pyrrolidine and azetidine compounds, compositions containing them and their use in methods of treating or preventing disorders or diseases associated with AT2 receptor function including neuropathic pain, inflammatory pain, conditions associated with neuronal hypersensitivity, impaired nerve conduction velocity, cell proliferation disorders, disorders associated with an imbalance between bone resorption and bone formation and disorders associated with aberrant nerve regeneration.

  本发明涉及可用于拮抗血管紧张素 II 2 型（AT2）受体的杂环化合物。更具体地说，本发明涉及吡咯烷和氮杂环丁烷化合物、含有它们的组合物及其在治疗或预防与 AT2 受体功能有关的紊乱或疾病的方法中的用途，这些紊乱或疾病包括神经性疼痛、炎症性疼痛、与神经元超敏性有关的病症、神经传导速度受损、细胞增殖紊乱、与骨吸收和骨形成失衡有关的紊乱以及与神经再生异常有关的紊乱。
• HETEROCYCLIC COMPOUNDS AND METHODS OF THEIR USE
  申请人：NOVARTIS AG

  公开号：US20170145032A1

  公开（公告）日：2017-05-25

  The present invention relates to heterocyclic compounds useful for antagonising angiotensin II Type 2 (AT 2 ) receptor. More particularly the invention relates to pyrrolidine and azetidine compounds, compositions containing them and their use in methods of treating or preventing disorders or diseases associated with AT 2 receptor function including neuropathic pain, inflammatory pain, conditions associated with neuronal hypersensitivity, impaired nerve conduction velocity, cell proliferation disorders, disorders associated with an imbalance between bone resorption and bone formation and disorders associated with aberrant nerve regeneration.
• US8507539B2
  申请人：——

  公开号：US8507539B2

  公开（公告）日：2013-08-13